https://doi.org/
Poster
NOT PEER REVIEWED
Download
metrics
VIEWS
262
 
downloads
237
CITE
How to cite this poster:
Greenbaum L, Legendre C, Babu S et al. Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data. F1000Posters 2013, 4:341 (poster)

Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data

Larry Greenbaum1, Christophe Legendre, Sunil Babu, Richard R Furman, Neil Sheerin, David Cohen, Frank Eitner, Yahsou Delmas, Camille L Bedrosian, Chantal Loirat
Published 30 May 2013
Author Affiliations
  • Metrics
  • 262 Views
  • 237 Downloads
Browse by related subjects
Published 30 May 2013

Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data

[version 1; not peer reviewed]

Larry Greenbaum1, Christophe Legendre, Sunil Babu, Richard R Furman, Neil Sheerin, David Cohen, Frank Eitner, Yahsou Delmas, Camille L Bedrosian, Chantal Loirat
Author Affiliations
1 Emory University, USA
Presented at
54th American Society of Hematology Annual Meeting 2012
Abstract
Competing Interests

Dr Licht has received fees for consultancy, research funding, and honoraria from Alexion Pharmaceuticals. Dr Muus has been a member of an advisory board for Alexion Pharmaceuticals. Dr Legendre has received compensation for participation in a speakers' bureau for Alexion Pharmaceuticals. Dr Bedrosian is an employee of Alexion Pharmaceuticals. Dr Loirat has been a coordinator of eculizumab trials for, and received honoraria for conferences from, Alexion Pharmaceuticals. Drs Furman, Sheerin, Cohen, Eitner, and Babu have have nothing to disclose.

This study was sponsored by Alexion Pharmaceuticals, Inc. Editorial support was provided by John Kincaid, MD, of Alexion Pharmaceuticals, Inc. Medical writing support was provided by Infusion Communications and supported by Alexion Pharmaceuticals, Inc.

Comments
0 Comments
 
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.